Minerva Neurosciences, Inc. Overview
Pro stress-test →Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The company is developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease.
Strategic Profile
Pro stress-test →Minerva raised up to $200 million in a private placement to fund a confirmatory Phase 3 trial of roluperidone, resubmission of its NDA, and preparation for a potential US commercial launch. The company co-developed seltorexant with Janssen Pharmaceutica NV for the treatment of insomnia disorder and adjunctive treatment of Major Depressive Disorder, with Janssen currently conducting Phase 3 trials.
Competitive Landscape
Pro stress-test →Minerva competes in the CNS treatment space with larger pharmaceutical companies. Janssen Pharmaceutica partner on seltorexant co-development. Primary competition comes from established antipsychotics and other pipeline programs targeting schizophrenia negative symptoms and Parkinson's disease.
Industry Context
Minerva Neurosciences, Inc. operates in Biopharmaceutical / CNS Therapeutics.
Key facts
Founded: 2007 · Headquarters: Burlington, MA, US · Employees: 8 · Revenue: $0 · Market cap: $50M-$100M